Paper: Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Oral and Poster Abstracts 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Luciano J. Costa, MD, PhD1, Nicholas Burwick, MD2, Andrzej Jakubowiak, MD, PhD3, Jonathan L. Kaufman, MD4, Fernando Cabanillas, MD5, Monique Dail, PhD6*, Sudeep Karve7*, Abdullah A. Masud, PhD8*, Xiaoqing Yang, PhD7*, Orlando F. Bueno7, Sarah Mudd, PhD8*, Jeremy A….

Read the full article here

Source: ash.confex.com

Categories: Hem/Oncs, Latest Headlines

Tags: ASH20, mmMRD, mmsm, NCT02899052, oncorad

Tweets with this article

Mike Thompson, MD, PhD, FASCO

MT @Rfonsi1 [12/6/20] Ven+Kd. ORR 92% in t(11;14). 15% MRD- (5). Critical study for those using less bortezomib. https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/A0wtHtH7SF https://t.co/Chp6PL3xbO

Mike Thompson, MD, PhD, FASCO

Assessment of MRD By NGS & FDG-PET in Pts w/ Relapsed/Refractory Multiple Myeloma Treated w/ Venetoclax in Combination w/ Carfilzomib and Dexamethasone (Kd-Ven) [Dec 6, 2020] @End_myeloma et al. #ASH20 Abst 2251 https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/IsY19hYzo0

Paper: Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma: Clinic al and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services…

Al-Ola A Abdallah MD April 18, 2024

COVID-19 vaccination and breakthrough infections in patients with cancer

Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…

Mike Thompson, MD, PhD, FASCO April 18, 2024

The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…

Mike Thompson, MD, PhD, FASCO April 18, 2024

COVID-19 and Cancer—A Review of the Registry-Based Pandemic Response

This review describes the registry efforts made during the COVID-19 pandemic with the aim of investigating and sharing information about the history, risk factors, and…

Mike Thompson, MD, PhD, FASCO April 18, 2024

The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

Mike Thompson, MD, PhD, FASCO April 18, 2024

Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

AbstractBackground. The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronaviru

Mike Thompson, MD, PhD, FASCO April 18, 2024

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of…

Mike Thompson, MD, PhD, FASCO April 18, 2024

Related Articles